<html><head><meta http-equiv="content-type" content="text/html; charset=utf-8"></head><body dir="auto">ROFL<div><br></div><div>Anyone paying attention to measured in kilograms ?</div><div><br></div><div>Happy April ! “Fools”<br><br><div dir="ltr"><div><span style="background-color: rgba(255, 255, 255, 0);">-- </span></div><div><span style="background-color: rgba(255, 255, 255, 0);"> J. Hellenthal</span></div><div><span style="background-color: rgba(255, 255, 255, 0);"><br></span></div><span style="background-color: rgba(255, 255, 255, 0);">The fact that there's a highway to Hell but only a stairway to Heaven says a lot about anticipated traffic volume.</span></div><div dir="ltr"><br><blockquote type="cite">On Apr 1, 2021, at 14:42, Carlos Alvarez <caalvarez@gmail.com> wrote:<br><br></blockquote></div><blockquote type="cite"><div dir="ltr"><div dir="ltr">Right? Where do they find all these blind doctors?<div><br></div></div><br><div class="gmail_quote"><div dir="ltr" class="gmail_attr">On Thu, Apr 1, 2021 at 12:37 PM Mary Lou Carey <<a href="mailto:marylou@backuptelecom.com">marylou@backuptelecom.com</a>> wrote:<br></div><blockquote class="gmail_quote" style="margin:0px 0px 0px 0.8ex;border-left:1px solid rgb(204,204,204);padding-left:1ex">Maybe they should open their eyes instead of doing a double-blind study! <br>
LOL!<br>
<br>
MARY LOU CAREY<br>
BackUP Telecom Consulting<br>
Office: 615-791-9969<br>
Cell: 615-796-1111<br>
<br>
On 2021-04-01 02:27 PM, Hiers, David wrote:<br>
> No AI here... This is classic, small-batch, hand-crafted, free-range,<br>
> organic, gluten-free content.<br>
> <br>
> <br>
> David<br>
> <br>
> <br>
> -----Original Message-----<br>
> From: VoiceOps <<a href="mailto:voiceops-bounces@voiceops.org" target="_blank">voiceops-bounces@voiceops.org</a>> On Behalf Of Alex <br>
> Balashov<br>
> Sent: Thursday, April 1, 2021 12:18 PM<br>
> To: Brandon Svec <<a href="mailto:bsvec@teamonesolutions.com" target="_blank">bsvec@teamonesolutions.com</a>><br>
> Cc: <a href="mailto:voiceops@voiceops.org" target="_blank">voiceops@voiceops.org</a><br>
> Subject: Re: [VoiceOps] Phase III clinical trials of Kamailio DMQ<br>
> <br>
> Let me make sure I understand your question correctly: it is your<br>
> belief or conjecture that this press release was automatically<br>
> generated by a machine learning system?<br>
> <br>
> —<br>
> Sent from mobile, with due apologies for brevity and errors.<br>
> <br>
>> On Apr 1, 2021, at 3:10 PM, Brandon Svec <<a href="mailto:bsvec@teamonesolutions.com" target="_blank">bsvec@teamonesolutions.com</a>> <br>
>> wrote:<br>
>> <br>
>> GPT-3? Happy April Fools Day.<br>
>> <br>
>> Brandon<br>
>> <br>
>>> On Mar 31, 2021, at 9:47 PM, Alex Balashov <br>
>>> <<a href="mailto:abalashov@evaristesys.com" target="_blank">abalashov@evaristesys.com</a>> wrote:<br>
>>> <br>
>>> For immediate release:<br>
>>> <br>
>>> GAINESVILLE, Florida (1 April 2021)--Evariste Systems, in partnership<br>
>>> with Posner | Palner Pharmaceuticals, are pleased to announce the<br>
>>> eagerly anticipated start of Phase III clinical trials of Kamailio<br>
>>> DMQ module replication.<br>
>>> <br>
>>> In this stage of the investigation of the promising replication<br>
>>> scheme, which was developed in record time, DMQ will be tested in a<br>
>>> rigourous, double-blind, controlled CI/CD process for large-scale<br>
>>> efficacy and continually monitored for safety in shorter and longer <br>
>>> terms.<br>
>>> <br>
>>> The now-concluded second phase established basic safety and Phase 2b<br>
>>> entailed a dose-finding study for the optimal number of batched<br>
>>> `dmq_usrloc` contacts per kilogram of cloud computing resource.<br>
>>> <br>
>>> The main cohort of the main sequence of the Phase III trial will<br>
>>> enroll 380 randomly selected, statistically representative Floridian<br>
>>> SIP registrars and<br>
>>> 5700 SIP dialogs, also in the state of Florida. When asked about the<br>
>>> disparity in the number of registrars versus dialogs, Alex Balashov<br>
>>> of Evariste said, "It is reflective of the small number of SIP<br>
>>> registrars in Florida; not to be indelicate, but consider the median <br>
>>> age of the population."<br>
>>> <br>
>>> As previously remarked upon in proceedings of the World SIP<br>
>>> Organisation (WSO), the choice of Florida as a venue attracted some<br>
>>> questions. We asked Fred Posner of Posner | Palner about the clinical<br>
>>> background informing this choice of replication study cohort:<br>
>>> <br>
>>> "Florida is a good place to find eventual consistency failures; the<br>
>>> open climate and reluctance to accept traditional data integrity<br>
>>> science would have sealed the deal, but when people started to drink<br>
>>> bleach here, I saw an opportunity."<br>
>>> <br>
>>> Evariste and Posner | Palner are aiming for a US Food & Drug<br>
>>> Administration EUA (Emergency Use Authorisation) for DMQ replication<br>
>>> as a prophylactic data redundancy and failover measure to ward off<br>
>>> the development of moderate to severe viral Sonus Haemorrhagic Fever <br>
>>> symptoms.<br>
>>> <br>
>>> Phase II studies have painted a promising a picture of the DMQ<br>
>>> architecture's ability to reduce moderate to severe symptoms and<br>
>>> associated 28-day mortality by more than 90%, albeit over a small<br>
>>> sample size and in enterprise patients with known pre-existing<br>
>>> comorbidities such as Session Border Controller and BroadSoft<br>
>>> Multi-System Inflammatory Syndrome. Phase III trials seek to bolster<br>
>>> quantums of broader efficacy, including efficacy for localised <br>
>>> outbreaks of small to medium business softswitch.<br>
>>> <br>
>>> Of the control group, Balashov said, "They will receive a standard<br>
>>> pipe-to-/dev/null placebo protocol, but with identical '200 OK'<br>
>>> confirmation messages. We proudly developed this approach in early<br>
>>> 2020 in consultation with the highest levels of the Trump<br>
>>> presidential administration; it is called TENP, or 'The Emperor's New<br>
>>> Potion.' It is a successor to that administration's previous approved <br>
>>> placebo protocol, SHTI - Small Hands, Tremendous Initiatives."<br>
>>> <br>
>>> Despite speculative autism and packet fragmentation claims by Florida<br>
>>> Governor Ron DeSantis, Balashov was quick to provide reassurance<br>
>>> about side effects from DMQ in the Phase III trial.<br>
>>> <br>
>>> "The incidence of severe allergies to plain-text UDP was within<br>
>>> standard deviation over the mean for all insecure replication, and<br>
>>> there's support for other transports on the way. Anyway, we have a<br>
>>> robust adverse effects reporting system in our issue tracker and<br>
>>> solid surveillance. Don't let partisan politics dissuade you from <br>
>>> allowing request lines with the KDMQ method."<br>
>>> <br>
>>> Other industry sources have reported that DMQ is not the only<br>
>>> replication investigation undertaken by Evariste and Posner | Palner,<br>
>>> although it is the only prophylactic suitable for the early infection<br>
>>> development and inflammatory phases of a broad class of SBC-complex<br>
>>> syndromes typically afflicting service providers. A recent IETF<br>
>>> preprint by the same authors has shown high-quality preliminary data<br>
>>> suggesting statistically significant improvement in morbidity<br>
>>> outcomes from Perimeta and Nokia via a later-stage therapeutic <br>
>>> intervention with a monoclonal, monorepo Github cocktail administered <br>
>>> intravenously.<br>
>>> <br>
>>> <br>
>>> --<br>
>>> Alex Balashov | Principal | Evariste Systems LLC<br>
>>> <br>
>>> Tel: +1-706-510-6800 / +1-800-250-5920 (toll-free)<br>
>>> Web: <a href="http://www.evaristesys.com/" rel="noreferrer" target="_blank">http://www.evaristesys.com/</a>, <a href="http://www.csrpswitch.com/" rel="noreferrer" target="_blank">http://www.csrpswitch.com/</a><br>
>>> _______________________________________________<br>
>>> VoiceOps mailing list<br>
>>> <a href="mailto:VoiceOps@voiceops.org" target="_blank">VoiceOps@voiceops.org</a><br>
>>> <a href="https://puck.nether.net/mailman/listinfo/voiceops" rel="noreferrer" target="_blank">https://puck.nether.net/mailman/listinfo/voiceops</a><br>
> _______________________________________________<br>
> VoiceOps mailing list<br>
> <a href="mailto:VoiceOps@voiceops.org" target="_blank">VoiceOps@voiceops.org</a><br>
> <a href="https://puck.nether.net/mailman/listinfo/voiceops" rel="noreferrer" target="_blank">https://puck.nether.net/mailman/listinfo/voiceops</a><br>
> <br>
> ----------------------------------------------------------------------<br>
> This message and any attachments are intended only for the use of the<br>
> addressee and may contain information that is privileged and<br>
> confidential. If the reader of the message is not the intended<br>
> recipient or an authorized representative of the intended recipient,<br>
> you are hereby notified that any dissemination of this communication<br>
> is strictly prohibited. If you have received this communication in<br>
> error, notify the sender immediately by return email and delete the<br>
> message and any attachments from your system.<br>
> _______________________________________________<br>
> VoiceOps mailing list<br>
> <a href="mailto:VoiceOps@voiceops.org" target="_blank">VoiceOps@voiceops.org</a><br>
> <a href="https://puck.nether.net/mailman/listinfo/voiceops" rel="noreferrer" target="_blank">https://puck.nether.net/mailman/listinfo/voiceops</a><br>
_______________________________________________<br>
VoiceOps mailing list<br>
<a href="mailto:VoiceOps@voiceops.org" target="_blank">VoiceOps@voiceops.org</a><br>
<a href="https://puck.nether.net/mailman/listinfo/voiceops" rel="noreferrer" target="_blank">https://puck.nether.net/mailman/listinfo/voiceops</a><br>
</blockquote></div>
<span>_______________________________________________</span><br><span>VoiceOps mailing list</span><br><span>VoiceOps@voiceops.org</span><br><span>https://puck.nether.net/mailman/listinfo/voiceops</span><br></div></blockquote></div></body></html>